Phase III trial did not show superiority of eribulin compared with capecitabine in metastatic breast cancer

Share :
Published: 12 Dec 2012
Views: 3177
Rating:
Save
Dr Peter Kaufman - Norris Cotton Cancer Center, New Hampshire, USA

At a press conference at SABCS 2012, Dr Peter Kaufman presents data on a A phase III multicenter study of eribulin mesylate in women with previously treated metastatic breast cancer failed to meet its co-primary endpoints of improved progression-free survival and overall survival compared with capecitabine.

 

Read more in ecancerNews.